the two groups: 3.5% for transfemoral CAS and 3.6% for
CEA (P Â¼ .96).
The recently completed ACT-1 Trial randomized 1453 patients 3:1 transfemoral CAS (1089) and CEA (364) in a noninferiority design.220 There was no difference in the
composite primary end point of death, stroke and MI between the transfem